Ellen J. Scherl, M.D. is Director of the Jill Roberts Inflammatory Bowel Disease Center ,the Jill Roberts Associate Professor of Medicine at Weill Medical College of Cornell University/ New York-Presbyterian Hospital in New York, New York and Adjunct Associate Professor of Medicine at Columbia University College of Physicians and Surgeons.

Her current interests encompass investigational therapies for ulcerative colitis and Crohn’s disease. She is a Fellow of the American College of Physicians (FACP), American Gastroenterological Associate Fellow (AGAF), and a member of numerous professional societies, including the American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE), and New York Society for Gastrointestinal Endoscopy (NYSGE). She lectures frequently on IBD at local, regional, and national meetings. She is chairperson of the Medical Advisory Committee of the Crohn’s and Colitis Foundation of America (New York Chapter).

She has established an IBD tissue bank and the ELLEN SCHERL/JILL ROBERTS IBD BIOBANK at Weill Medical College of Cornell University/ New York-Presbyterian Hospital, has collaborated with researchers at Cornell University to identify a novel E. Coli associated with Crohn’s disease and continues to collaborate with Weill Medical College of Cornell University/ New York-Presbyterian Hospital researchers investigating the immunogenetics and pathobiology of IBD.

She is an editorial reviewer for the IBD Journal, Journal of Clinical Gastroenterology, Gastrointestinal Endoscopy, and Gastroenterology and Hepatology. She is the co-author of Crohn’s Disease of the Small Intestine in Gastroenterology and Hepatology: The Comprehensive Visual Reference. Also, co-editor The Life Cycle of IBD and co-author of An Interactive Dialogue on IBD.
co-editor of Ulerative Colitis:The Complete Guide To Medical Management and Crohn’s Disease: The Complete Guide To Medical Management and of The Changing World Of IBD.

She has extensive experience as an investigator in many clinical trials and is currently participating in national multicenter trials and investigator initiated trials focusing on both ulcerative colitis and Crohn’s disease.